Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Heron Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected seven directors, ratified Withum Smith+Brown, PC as auditor for the year ending December 31, 2026, and approved executive compensation on a nonbinding advisory basis.
They also approved amendments to the company’s equity plans, increasing shares authorized under the 2007 Equity Incentive Plan by an additional 16,560,000 shares and under the 1997 Employee Stock Purchase Plan by an additional 10,000,000 shares. Stockholders further ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan. As of the April 14, 2026 record date, 188,638,866 common shares were outstanding, with 141,927,939 shares represented at the meeting, constituting a quorum.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding on record date: 188,638,866 shares
Shares represented at meeting: 141,927,939 shares
Equity Incentive Plan increase: 16,560,000 shares
+3 more
6 metrics
Shares outstanding on record date
188,638,866 shares
Common stock outstanding as of April 14, 2026
Shares represented at meeting
141,927,939 shares
Common stock represented in person or by proxy at 2026 Annual Meeting
Equity Incentive Plan increase
16,560,000 shares
Additional common shares authorized under 2007 Equity Incentive Plan
ESPP share increase
10,000,000 shares
Additional common shares authorized under 1997 Employee Stock Purchase Plan
Say-on-pay votes For
77,315,474 votes
Advisory approval of 2025 executive compensation
Auditor ratification votes For
139,715,514 votes
Ratification of Withum Smith+Brown, PC for 2026 fiscal year
Key Terms
nonbinding advisory basis, Equity Incentive Plan, Employee Stock Purchase Plan, Tax Benefits Preservation Plan
4 terms
nonbinding advisory basis financial
"to approve, on a nonbinding advisory basis, compensation paid to the Company’s Named Executive Officers"
Equity Incentive Plan financial
"amendment and restatement of the Company’s 2007 Amended and Restated Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Employee Stock Purchase Plan financial
"amendment to the Company's 1997 Employee Stock Purchase Plan, as amended"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Tax Benefits Preservation Plan financial
"to ratify, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan"
A tax benefits preservation plan is a company’s set of policies and actions designed to protect valuable tax attributes—like net operating losses, credits, or favorable tax statuses—when the business changes ownership, reorganizes, or conducts large transactions. Investors care because preserving these tax benefits can reduce future tax bills and improve cash flow, much like keeping a valuable coupon valid so future purchases cost less, which can affect earnings and valuation.
FAQ
What did Heron Therapeutics (HRTX) stockholders vote on at the 2026 Annual Meeting?
Heron Therapeutics stockholders voted on six key proposals. These included electing seven directors, ratifying the independent auditor, advisory approval of executive compensation, expanding the equity incentive and employee stock purchase plans, and ratifying the adoption of a Tax Benefits Preservation Plan.
Were all director nominees elected at Heron Therapeutics’ 2026 Annual Meeting?
Yes, all seven director nominees were elected. Candidates including Craig Collard, Thomas Cusack, Sharmila Dissanaike, Craig Johnson, Michael Kaseta, Adam Morgan, and Christian Waage each received more votes “For” than “Against,” with substantial broker non-votes reported separately.
Did Heron Therapeutics (HRTX) stockholders approve executive compensation at the 2026 meeting?
Stockholders approved executive pay on an advisory basis. The say-on-pay proposal for compensation paid to Named Executive Officers for the year ended December 31, 2025 received 77,315,474 votes “For,” 12,117,861 “Against,” and 2,378,521 abstentions, with 50,116,083 broker non-votes.
What were the voting results for Heron Therapeutics’ 2026 auditor ratification?
Stockholders strongly ratified the company’s independent auditor. The appointment of Withum Smith+Brown, PC for the fiscal year ending December 31, 2026 received 139,715,514 votes “For,” 1,706,193 “Against,” and 506,232 abstentions, with no broker non-votes reported.
What is the Tax Benefits Preservation Plan ratified by Heron Therapeutics stockholders?
Stockholders ratified adoption of a Tax Benefits Preservation Plan. The advisory ratification received 88,182,895 votes “For,” 3,442,815 “Against,” and 186,146 abstentions, with 50,116,083 broker non-votes, signaling support for measures related to preserving certain tax attributes.